2% Lidocaine Plus 0.5% Bupivacaine Versus 0.5% Bupivacaine in Brachial Block for Creation of Arteriovenous (AV) Fistula

Comparison of Onset of Action Between 2% Lidocaine Plus 0.5% Bupivacaine and 0.5% Bupivacaine in Brachial Plexus Anesthesia for Creation of Arteriovenous Fistula in ESRD Patient

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00993746

Enrollment

Registered

2009-10-12

Start date

2009-10-31

Completion date

2011-09-30

Last updated

2010-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infraclavicular Brachial Plexus Block

Keywords

Ultrasound guided infraclavicular brachial plexus block, Bupivacaine, Bupivacaine plus lidocaine, End stage renal disease, Arteriovenous fistula

Brief summary

Will the technique of adding lidocaine to bupivacaine fasten the onset of bupivacaine alone for infraclavicular brachial plexus block in end-stage renal disease (ESRD) patient?

Interventions

DRUGBupivacaine plus lidocaine

Bupivacaine 20 ml plus lidocaine 10 ml

DRUGBupivacaine 30 ml

Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ESRD patient for AVF procedure * age \>17 year * BMI 20-35 kg/m2 * communicable

Exclusion criteria

* BMI \> 35 kg/m2 BMI \< 20 kg/m2 หรือ BW \< 35 kg * History of allergy to local anesthetic drugs * Pre-operative neurological deficit, Neuromuscular disorder หรือ old CVA * Psychiatric disorder * Coagulation disorder * Uncontrolled seizure * Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
onset of sensory block	24 hour

Secondary

Measure	Time frame
onset of motor block	24 hour

Countries

Thailand

Contacts

Primary ContactOrawan Pongraweewan, MD,FRCA

pongraweewan@yahoo.com6681-4317599

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026